Myriad Genetics (LTS:0K3W) Institutional Ownership : 61.35% (As of Jun. 07, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Myriad Genetics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Myriad Genetics's institutional ownership is 61.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Myriad Genetics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Myriad Genetics's Float Percentage Of Total Shares Outstanding is 71.33%.

Myriad Genetics Institutional Ownership Historical Data

The historical data trend for Myriad Genetics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Institutional Ownership Chart

Myriad Genetics Historical Data

The historical data trend for Myriad Genetics can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	64.84	64.23	60.28	57.37	59.80	59.78	60.21	61.67	61.33	61.35

Myriad Genetics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Myriad Genetics (LTS:0K3W) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (LTS:0K3W) » Definitions » Institutional Ownership

Comparable Companies

NEO TWST VCYT NEOG GH SHC OPK LAB CDNA CSTL TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

MYGN:USA MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics (LTS:0K3W) Headlines

No Headlines